Sign In
Buy ZYXI
$0.125
+0 (+0%)
At Close: Mar 20, 2026
Zynex, Inc. to Announce Fourth Quarter and Full Year 2022 Financial Results
09:15am, Thursday, 23'rd Feb 2023
ENGLEWOOD, Colo. , Feb. 23, 2023 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain
Top 5 Health Care Stocks That Could Blast Off This Month - Azenta (NASDAQ:AZTA), Amgen (NASDAQ:AMGN)
08:28am, Monday, 13'th Feb 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Zynex Is A Quality Company, But You Must Pay For Quality
10:30pm, Tuesday, 31'st Jan 2023
Products sold in the past by Zynex for pain management have failed to penetrate the market. Zynex's new products are radically different from their predecessors: more specific and innovative.
3 Small-Cap Bargains Gurus Are Buying
06:10pm, Monday, 05'th Dec 2022
According to recent data from Bank of America's ( BAC , Financial) BofA Securities, the small-cap stocks on the Russell 2000 index are now trading at their lowest average forward price-earnings ratio
Zynex: A Growing Stock In A Bearish Market
02:15pm, Wednesday, 23'rd Nov 2022
Zynex, Inc.'s business is inflation-resistant, and the monitor division could be a game changer. Quarterly results were positive, and Zynex continues to operate at its best.
Zynex, Inc. (ZYXI) Q3 2022 Earnings Call Transcript
08:47pm, Thursday, 27'th Oct 2022
Zynex, Inc. (NASDAQ:ZYXI ) Q3 2022 Earnings Conference Call October 27, 2022 4:15 AM ET Company Participants Louisa Smith – Investor Relations-Gilmartin Group Thomas Sandgaard – Chairman, Presiden
Zynex Inc. (ZYXI) Surpasses Q3 Earnings and Revenue Estimates
07:33pm, Thursday, 27'th Oct 2022
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 8.33% and 0.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
7 Under-the-Radar Growth Stocks With 200% Growth Potential
12:04pm, Monday, 17'th Oct 2022
Rising interest rates and growing fears of a recession have sent growth stocks plunging in the past year. Yet while some growth names have deservingly moved to lower prices and could keep tumbling, th
Short Squeeze Candidate With Low PEG Ratio: Zynex
03:48pm, Wednesday, 05'th Oct 2022
Zynex has succumbed to extensive short selling in 2021-22 that may be in the process of reconsidering bearish bets. Projected growth rates for the company are exceptionally positive, on new product re
7 Hot Small-Cap Stocks to Buy in September
06:45am, Friday, 02'nd Sep 2022
In general, finding small-cap stocks to buy can be somewhat fraught. These are stocks with market capitalizations between roughly $300 million and $2 billion.
Zynex Medical to Participate in H.C. Wainwright Annual Global Investment Conference
09:15am, Thursday, 01'st Sep 2022
ENGLEWOOD, Colo. , Sept. 1, 2022 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pa
Zynex Cures The Pain Of Its Shareholders: Q2 Results
11:44am, Monday, 01'st Aug 2022
Zynex beat analysts' estimates despite the recession. Zynex is committed to bringing value to its shareholders with a new share buyback round.
Zynex, Inc. (ZYXI) CEO Thomas Sandgard on Q2 2022 Results - Earnings Call Transcript
09:16pm, Thursday, 28'th Jul 2022
Zynex, Inc. (NASDAQ:ZYXI ) Q2 2022 Results Conference Call July 28, 2022 4:15 PM ET Company Participants Louisa Smith - Investor Relations-Gilmartin Group Thomas Sandgaard - Chairman, President and Ch
Zynex, Inc. to Announce Second Quarter 2022 Financial Results
09:15am, Wednesday, 20'th Jul 2022
ENGLEWOOD, Colo. , July 20, 2022 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain
Zynex Inc. (ZYXI) Q1 Earnings Miss Estimates
09:25pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of -40% and 0.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
